8 June 2026 - Alvotech today announced that the US FDA has accepted for review a biologics license application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) lyophilised vial for intravenous administration.

Under a partnership with Teva Pharmaceutical Industries, Alvotech is responsible for development and manufacturing of AVT16, while Teva is responsible for commercialisation.

Read Alvotech press release